Nova Mentis Will Test Potential Psychedelic Treatment in Animal Model

Nova Mentis Will Test Potential Psychedelic Treatment in Animal Model

287261

Nova Mentis Will Test Potential Psychedelic Treatment in Animal Model

Nova Mentis is expanding its preclinical pipeline to test a psychedelic treatment known as PLZ-1013 in an animal model of fragile X syndrome. The psychedelic compound, psilocybin, is being investigated as a potential behavioral therapy for fragile X. Researchers at the Canada-based company are collaborating with Viviana Trezza, PhD, from Roma Tre University, in Italy, to test PLZ-1013, a psilocybin compound. The aim is to assess its potential efficacy and determine therapeutic doses to be…

You must be logged in to read/download the full post.